AZ having proved to themselves that the dendrimer works may now activate the licence on other targets recall the paper presented in the UK by Aztrezenica was more about how to use the dendrimer, quality control and testing of the dendrimer than it was about the drug clinical trial was mentioned by some at the time this looked more like an exercise in how to present dendrimer testing to the FDA than anything else.
Ann: Partnered Program Update, page-10
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $41.31M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.9¢ | $14.97K | 151.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 372123 | 9.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 5042 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| SPL (ASX) Chart |